In FY2020, Dr. Reddy’s Laboratories Limited has implemented 182 energy conservation projects across various business units and accrued savings of Rs. 196 million (Rs.19.6 cr). It has also generated 127.15 TJ of energy using biomass/rice husk briquettes, thus eliminating GHG emission by 12,997 tons of CO2e.
“The share of renewable energy in our total energy consumption has also increased.”, the company Annual Report 2019-20 said.
Solar energy consumption for FY2020 is around 65.96 million kwh, thereby we have avoided carbon emission by 54,084 tons of CO2e. We have also generated 127.15 TJ of energy using biomass/rice husk briquettes, thus eliminating GHG emission by 12,997 tons of CO2e, the comapany said.
Solar power supply started from 15 MW joint venture plants to CTO-1, CTO-2, CTO-3, CTO-5, FTO-2, FTO-3 and Biologics plants. 3 MW Roof top solar power plants installation works in progress at FTO-2, FTO-7, FTO-9, FTO-PU1 and FTO-11 plants and 350 KW is already commissioned, the report said.
The comany contributed Rs. 275.3 million (Rs. 27.53 cr) for community development under Corporate Social Responsibility (CSR) mandate. It is 2.25% of the average net profi ts of the company made during the immediately three preceding financial years.
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. The major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Its major markets include – USA, India, Russia & CIS countries, and Europe.
